Bayer Net Change in Short-term Investments 2012-2026 | BAYRY
Bayer annual/quarterly net change in short-term investments history and growth rate from 2012 to 2026. Net change in short-term investments can be defined as the net cash flows from the sale and purchase of investments defined to be short-term, generally with maturities of less than one year from the purchase date.
- Bayer net change in short-term investments for the quarter ending March 31, 2026 was $0.527B, a 28.78% decline year-over-year.
- Bayer net change in short-term investments for the twelve months ending March 31, 2026 was $2.840B, a 56.19% decline year-over-year.
- Bayer annual net change in short-term investments for 2025 was $0.787B, a 71.55% decline from 2024.
- Bayer annual net change in short-term investments for 2024 was $2.768B, a 2363.3% decline from 2023.
- Bayer annual net change in short-term investments for 2023 was $-0.122B, a 93.65% decline from 2022.
|
Bayer Annual Net Change in Short-term Investments (Millions of US $) |
|
|---|---|
| 2025 | $787 |
| 2024 | $2,768 |
| 2023 | $-122 |
| 2022 | $-1,926 |
| 2021 | $5,046 |
| 2020 | $-280 |
| 2019 | $-339 |
| 2018 | $3,352 |
| 2017 | $1,744 |
| 2016 | $-6,247 |
| 2015 | $-382 |
| 2014 | $-222 |
| 2013 | $129 |
| 2012 | $1,709 |
| 2011 | N/A |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $46.178B | $51.552B |
| Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |